Merck Millipore - Millipore S.A.S.

Merck Millipore - Millipore S.A.S.
Share

Advances in genome editing using “DNA scissors” such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) help to more quickly discover and produce new therapeutic options for conditions that are difficult to treat. Researchers are working, for example, to identify genes that are associated with cancer. The vision is to disable or...

Divestment major step towards strategic alignment of R&D resources to Healthcare priorities
Focus on innovative drug development of high quality and first-to-market best-in-disease assets
Merck receives upfront purchase price, milestone payments and royalties on potential product sales
Closing expected in the second half of 2017
Merck, a...

Merck Millipore - Millipore S.A.S.

 •  December 1, 2016

Merck to be the exclusive supplier of novel enzymes for polymerase chain reaction (PCR) and quantitative real-time PCR, for all countries except the U.S., Brazil and Japan
Exclusive global distributor for Roche’s biochemical reagents portfolio since 2015
Merck, a leading life science and technology company, today announced an expansion of its...

Merck Millipore - Millipore S.A.S.

 •  November 29, 2016

Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for avelumab, which was submitted by EMD Serono, the biopharmaceutical business of Merck in the US and Canada. This review relates to avelumab’s proposed use in patients with...

Merck Millipore - Millipore S.A.S.

 •  November 15, 2016

Publication of Merck KGaA, Darmstadt, Germany. There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD...